Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting

BERKELEY, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the presentation of positive preclinical data for its allogeneic, immune-cloaked, anti-BCMA CAR-T cell therapy candidate, CB-011, being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM). The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022, in New Orleans.

The data demonstrate that CB-011 CAR-T cells are cytotoxic against BCMA-expressing tumor cells and are resistant to killing by both allogeneic T cells and natural killer (NK) cells. In a tumor xenograft model of MM, CAR-T cells expressing a CAR containing a proprietary humanized anti-BCMA antibody fragment (scFv) that is used in CB-011 markedly prolonged antitumor activity compared to CAR-T cells expressing a benchmark anti-BCMA CAR. Caribou is conducting Investigational New Drug (IND) application-enabling safety studies to support a planned IND application submission in 2022 for CB-011 in r/r MM.

Details of the poster presentation are as follows:

Title: A BCMA-specific allogeneic CAR-T cell therapy (CB-011) genome-engineered to express an HLA-E fusion transgene to prevent immune cell rejection
Presenter: Émilie Degagné, Ph.D., Senior Scientist I
Date and Time: Sunday, April 10, 2022, 1:30 – 5:00 pm CT